V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20084150 | 20135090 | 1.84 | 83 | Adjuvant (A) | 2018-06-06 | 2018-06-07 | EOF | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100861511 |
| 20092444 | 20135091 | 1.82 | 68 | null | 2013-06-04 | 2017-05-13 | Ifosfamide | 02 | null | HEPATOBLASTOMA VHR BLOCK C CARBO (AUC6.6)/DOX | 100058981 |
| 20094036 | 20135092 | 1.77 | 83 | 03 | 2019-09-11 | 2019-09-18 | CHOP R - 21 days | 02 | N | FOCUS4 TRIAL | 101473769 |
| 20101114 | 20135093 | 1.55 | 56.4 | Curative (C) | 2021-05-16 | 2021-06-03 | Temozolomide + RT | 01 | N | COSMIC TRIAL | 101515352 |
| 20101840 | 20135094 | 1.6 | 12.7 | Palliative (P) | 2018-09-16 | 2018-09-16 | Cetuximab + Irinotecan (Cycle 1) | 02 | N | BORTEZOMIB + PANOBINOSTAT | 100678107 |
| 20104742 | 20135095 | 1.77 | 71 | Palliative (P) | 2021-01-16 | 2021-02-14 | CISPLATIN + FLUOROURACIL + Trastuzumab | 02 | null | FOCUS4 TRIAL | 101354924 |
| 20106338 | 20135096 | 1.79 | 96 | Palliative (P) | 2019-11-20 | 2019-11-27 | CEDAR trial | 02 | N | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 101280589 |
| 20107276 | 20135098 | 1.75 | 122.2 | Palliative (P) | 2019-05-27 | 2019-07-28 | Liposomal Doxorubicin (Caelyx) | 02 | N | VINORELBINE | 100470913 |
| 20112612 | 20135099 | 0 | 64.6 | Palliative (P) | 2017-12-27 | 2018-01-10 | CISPLATIN + RALTITREXED + Trastuzumab | 02 | N | DABRAFENIB + TRAMETINIB | 101479073 |
| 20112952 | 20135100 | 1.76 | 98.8 | null | 2018-07-01 | 2018-07-05 | CHOP R - 21 days | 02 | null | CAPECITABINE + CETUXIMAB + OXALIPLATIN | 101726390 |
| 20116918 | 20135102 | 1.47 | 56.7 | Palliative (P) | 2019-04-25 | 2019-04-25 | PHITT B or C Cisplatin | N | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100663476 |
| 20118797 | 20135104 | 1.57 | 97 | Palliative (P) | 2017-12-28 | 2017-12-28 | Cape+Cetuximab+Oxalip (2 wk) Maint | 02 | N | PHITT B OR C CISPLATIN | 100817136 |
| 20122293 | 20135106 | 1.71 | 78 | Palliative (P) | 2018-10-14 | 2018-11-12 | Hydroxycarbamide | null | N | GEMCITABINE + OXALIPLATIN | 100099904 |
| 20123736 | 20135107 | 1.6 | 115.9 | Neo-adjuvant (N) | 2017-08-13 | 2017-09-04 | null | N | N | ECARBOX | 101188430 |
| 20124933 | 20135108 | 1.71 | 85.8 | Palliative (P) | 2018-10-25 | 2018-10-29 | SCOPE 2 TRIAL | 02 | null | CARBOPLATIN + PEMETREXED | 101624058 |
| 20133725 | 20135111 | 1.55 | 18.1 | null | null | 2019-02-14 | Cape+Cetuximab+Oxalip (2 wk) Maint | N | null | CISPLATIN + FLUOROURACIL + RT | 101658038 |
| 20134501 | 20135112 | 1.8 | 56.8 | null | 2019-10-27 | 2019-12-20 | Irinotecan + Raltitrexed | 02 | N | CARBOPLATIN + EPIRUBICIN + FLUOROURACIL | 100943866 |
| 20135266 | 20135113 | 1.9 | 108.8 | null | 2019-07-20 | 2019-08-23 | INTERAACT trial | 2 | null | CAPE + OXALIPLATIN + TRASTUZUMAB | 101265458 |
| 20145424 | 20135115 | 1.65 | 81.6 | null | 2021-01-25 | 2021-02-06 | SCOPE 2 TRIAL | 02 | null | EW EUROEWING 2012 ARM B VDC | 101806526 |
| 20145785 | 20135116 | 1.79 | 87.1 | null | 2021-07-06 | 2021-07-06 | Bevacizumab + Capecitabine | 02 | N | CAPECITABINE + CETUXIMAB + OXALIPATIN | 101457750 |
| 20146565 | 20135117 | 1.55 | 66 | Curative (C) | 2018-04-18 | 2018-04-18 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | 02 | N | BRIGATINIB | 100751944 |
| 20148062 | 20135118 | 1.81 | 85.4 | 03 | 2020-04-03 | 2020-04-21 | DA 3 + 10 | 02 | N | DOCETAXEL + NINTEDANIB | 100374110 |
| 20152132 | 20135120 | 1.55 | 68.2 | Palliative (P) | null | 2021-06-09 | Cisplatin + Docetaxel | 01 | null | IPILIMUMAB + NIVOLUMAB | 100979015 |
| 20153140 | 20135121 | 1.65 | 70 | Neo-adjuvant (N) | 2019-05-07 | 2019-05-07 | Capecitabine + Streptozocin | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100043799 |
| 20154672 | 20135123 | 1.71 | null | Palliative (P) | 2020-02-04 | 2020-02-04 | VINORELBINE | 02 | N | CYCLOPHOSPHAMIDE HIGH DOSE | 100611559 |
| 20154905 | 20135125 | 1.8 | 68.9 | Palliative (P) | 2018-12-25 | 2018-12-25 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | AZACITIDINE | 101838371 |
| 20155961 | 20135126 | null | 64.1 | null | 2019-11-04 | 2019-11-25 | DACTINOMYCIN + CYCLO + VINCRISTINE | 01 | null | MCX | 101061155 |
| 20159240 | 20135127 | 1.8 | 62.1 | Palliative (P) | 2015-08-30 | 2016-12-14 | EEF or EOF | N | null | PERTUZUMAB + TRASTUZUMAB | 101608329 |
| 20159425 | 20135128 | 1.72 | 62.2 | null | 2019-12-19 | 2019-12-20 | Cisplatin + Docetaxel +Fluorouracil | null | null | RUCAPARIB | 101448302 |
| 20160508 | 20135129 | 1.57 | 57 | Curative (C) | 2018-06-17 | 2018-07-15 | CAPECITABINE + MITOMYCIN + RT | N | N | IRINOTECAN + MDG + PANITUMUMAB | 100589339 |
| 20166245 | 20135130 | 1.53 | 52.5 | Curative (C) | 2021-12-04 | 2021-12-30 | Cisplatin + Docetaxel +Fluorouracil | N | null | BORTEZOMIB | 100000864 |
| 20166846 | 20135131 | 1.8 | 79.3 | null | 2021-12-11 | 2021-12-20 | ABVD | 02 | N | CISPLATIN + TEYSUNO | 100349634 |
| 20175995 | 20135133 | 1.81 | 66.85 | 03 | 2021-03-26 | 2021-04-01 | CARBOPLATIN + VINORELBINE | 02 | N | PEMIGATINIB | 100735644 |
| 20176608 | 20135134 | 1.85 | null | Palliative (P) | 2021-02-16 | 2021-04-07 | CISPLATIN + RALTITREXED | 02 | N | CAPECITABINE + CISPLATIN + STREPTOZOCIN | 101408911 |
| 20183463 | 20135136 | 1.72 | 52.2 | Palliative (P) | 2016-10-17 | 2016-10-28 | EEF or EOF | N | N | CAP + RT | 101746146 |
| 20187912 | 20135137 | 1.52 | 57 | Palliative (P) | 2019-12-24 | 2020-01-14 | ISATUXIMAB + POMALIDOMIDE | 2 | N | CYTARABINE + DAUNORUBICIN + GEMTUZUMAB OZOGAMICIN | 101522207 |
| 20190352 | 20135138 | 1.65 | 80.2 | Adjuvant (A) | 2019-06-09 | 2019-08-06 | MITOMYCIN | 02 | N | CAPECITABINE + LOMUSTINE | 101072858 |
| 20199357 | 20135139 | 1.71 | 73 | null | 2019-08-31 | 2019-08-31 | COSMIC TRIAL | 02 | null | CAPE + OXALIPLATIN + TRASTUZUMAB | 100441603 |
| 20200913 | 20135140 | 1.57 | 67.65 | Neo-adjuvant (N) | 2021-04-05 | 2021-05-05 | Gemcitabine + Oxaliplatin | 01 | N | PONATINIB | 100060037 |
| 20201838 | 20135142 | 1.8 | null | Palliative (P) | 2020-02-07 | 2020-02-09 | CAPECITABINE + OXALIPLATIN + PEMBROLIZUMAB | 02 | Y | PALBOCICLIB | 101521517 |
| 20204646 | 20135143 | 1.47 | 101.8 | Adjuvant (A) | 2022-04-09 | 2022-04-12 | VINORELBINE | 2 | N | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 101654137 |
| 20204722 | 20135144 | null | null | Palliative (P) | 2017-08-09 | 2017-08-17 | PERTUZUMAB + TRASTUZUMAB | 02 | null | GO2 TRIAL | 100936390 |
| 20205619 | 20135145 | 1.54 | 47.4 | Curative (C) | 2018-10-16 | 2018-10-16 | NAB PACLITAXEL | 01 | null | ABEMACICLIB + FULVESTRANT | 101747743 |
| 20210958 | 20135146 | 1.6 | 61.7 | Neo-adjuvant (N) | 2018-09-26 | 2018-10-10 | Temozolomide + RT | 02 | N | STREPTOZOCIN + MDG | 100639536 |
| 20211066 | 20135147 | 1.81 | 74.3 | Palliative (P) | 2021-12-20 | 2021-12-21 | null | N | N | PLATO TRIAL | 100559799 |
| 20212094 | 20135148 | 1.69 | 65.2 | Palliative (P) | 2017-04-06 | 2017-05-04 | FCarboSt | N | N | BACILLUS CALMETTE-GUERIN | 100203168 |
| 20212159 | 20135149 | 1.75 | 47.6 | null | 2016-06-27 | 2016-06-27 | AML 19 TRIAL | 02 | N | CARBOPLATIN + PEMETREXED | 100016305 |
| 20215936 | 20135150 | 1.56 | 53 | Palliative (P) | 2019-09-16 | 2019-09-16 | Hydroxycarbamide | 02 | N | CHLORAMBUCIL + OBINUTUZUMAB | 101630201 |
| 20219760 | 20135152 | 1.84 | 47.2 | null | 2018-01-25 | 2018-01-28 | RAMUCIRUMAB | 01 | null | LETROZOLE + RIBOCICLIB | 100369989 |
| 20220027 | 20135153 | 1.71 | 61.1 | null | 2019-01-28 | 2019-01-28 | CABOZANTINIB | 02 | N | OXALIPLATIN + MDG + PANITUMUMAB | 101100293 |